-
American women are one step closer to having a contraceptive implant option with the recent Food and Drug Administration (FDA) issuance of approvable status for Implanon, the single-rod contraceptive implant from Organon (West Orange, NJ).
-
-
-
Results from the estrogen-progestin arm of the Womens Health Initiative confirm (after central adjudication of the diagnoses) an increase in venous thrombosis associated with a standard dose of postmenopausal hormone therapy.
-
Nearly 70% of patients achieving a CR after primary therapy eventually recurred. Most recurrences occurred more than 6 months from completion of primary chemotherapy, and the use of second line agents at the time of recurrence was effective.
-
Two premenopausal patients with resis tant endometriosis were successfully treated with a combination of the aromatase inhibitor anastrozole, Prometrium, calcitrol, and rofecoxib. Both patients had been diagnosed with endometriosis via laparoscopy, and had undergone GnRH suppression.
-
Smith and colleagues performed a case-control study of venous thrombosis and hormone users in postmenopausal women registered in a large health maintenance organization (the Group Health Cooperative) in the state of Washington.
-
The Infection Risk of Acid-Suppressing Drugs; Is Rosuvastatin As Safe As Other Statins?; Which Estrogen Preparation is the Safest?; FDA Actions.
-
-
